Download PDFPDF
Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    About “Scleroderma lung study"

    Dear Sir,

    We have read the interesting paper of Clements PJ et al (1) as well as their previous article “Cyclophosphamide versus placebo in scleroderma lung disease” (2).

    We think the Authors should give information about the autoantibody status of the patients; the recent analysis of the very large EUSTAR cohort of scleroderma cases demonstrated that autoantibody specificity is more closely related to or...

    Show More
    Conflict of Interest:
    None declared.